https://scholars.lib.ntu.edu.tw/handle/123456789/625985
標題: | Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis | 作者: | HSIANG-FONG KAO HUAI-CHENG HUANG BIN-CHI LIAO RUEY-LONG HONG |
關鍵字: | Afatinib; Anti-PD-1; Head and neck squamous cell carcinoma; Immunotherapy; Pembrolizumab | 公開日期: | 28-十一月-2022 | 卷: | 22 | 期: | 1 | 來源出版物: | BMC cancer | 摘要: | The optimal duration of anti-PD-1 for cancer therapy has not been tested, especially when using combination therapy. Epidermal growth factor receptor (EGFR) pathway blocker was the top compound that enhanced T-cell killing of tumor cells in a high-throughput immune-oncology screen, possibly by stimulate the antigen presentation machinery and other mechanisms. We explored the effect of combination of EGFR inhibition with a short course of anti-PD-1 therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/625985 | ISSN: | 1471-2407 | DOI: | 10.1186/s12885-022-10343-7 |
顯示於: | 醫學院附設癌醫中心醫院(臺大癌醫) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。